**Appendix Table D114. Risk of bias in placebo controlled randomized controlled clinical trials of adverse effects with drugs for migraine prevention**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Drugs** | **High** | **Low** | **Medium** | **Total** | **% Low** |
| Topiramate | 0 | 6 | 5 | 11 | 54.5 |
| Divalproex | 0 | 1 | 1 | 2 | 50 |
| Valproate | 0 | 0 | 1 | 1 | 0 |
| Propranolol | 0 | 1 | 3 | 4 | 25 |
| Timolol | 0 | 0 | 1 | 1 | 0 |
| Lamotrigine | 0 | 1 | 0 | 1 | 100 |
| Carbamazepine | 0 | 0 | 1 | 1 | 0 |
| Acetazolamide | 0 | 1 | 0 | 1 | 100 |
| Amitriptyline | 0 | 0 | 3 | 3 | 0 |
| Nadolol | 0 | 1 | 0 | 1 | 100 |
| Metoprolol | 0 | 0 | 3 | 3 | 0 |
| Atenolol | 0 | 0 | 2 | 2 | 0 |
| Alprenolol | 0 | 0 | 1 | 1 | 0 |
| Pindolol | 0 | 0 | 1 | 1 | 0 |
| Captopril | 0 | 1 | 0 | 1 | 100 |
| Lisinopril | 0 | 1 | 0 | 1 | 100 |
| Telmisartan | 1 | 0 | 0 | 1 | 0 |
| Candesartan | 0 | 1 | 0 | 1 | 100 |
| Nimodipine | 0 | 1 | 3 | 4 | 25 |
| Verapamil | 0 | 0 | 1 | 1 | 0 |
| Nicardipine | 0 | 0 | 1 | 1 | 0 |
| Nifedipine | 1 | 0 | 1 | 2 | 0 |
| Clonidine | 1 | 1 | 4 | 6 | 16.67 |
| Dihydroergocryptine | 0 | 0 | 1 | 1 | 0 |
| Dihydroergotamine | 0 | 1 | 2 | 3 | 33.33 |
| Lisuride | 0 | 0 | 1 | 1 | 0 |
| Methysergide | 0 | 0 | 1 | 1 | 0 |
| Tizanidine | 0 | 0 | 1 | 1 | 0 |
| Montelukast | 0 | 1 | 0 | 1 | 100 |
| Femoxetine | 0 | 0 | 3 | 3 | 0 |
| Fluoxetine | 1 | 0 | 3 | 4 | 0 |
| Gabapentin | 0 | 0 | 2 | 2 | 0 |
| Indomethacin | 0 | 0 | 1 | 1 | 0 |
| Induprofen | 0 | 0 | 1 | 1 | 0 |
| Ketoprofen | 0 | 0 | 1 | 1 | 0 |
| Naproxen sodium | 2 | 0 | 0 | 2 | 0 |
| Magnesium | 0 | 2 | 0 | 2 | 100 |
| Oxcarbazepine | 0 | 1 | 0 | 1 | 100 |
| Tolfenamic Acid | 0 | 0 | 1 | 1 | 0 |
| Tonabersat | 0 | 1 | 0 | 1 | 100 |
| TOTAL\*(includes flunarizine trials) | 7 | 22 | 54 | 83 | 26.51 |